Switch theme
Sign up to access all valuation multiples
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
2021
52
LTM Revenue $2.1M
LTM EBITDA -$96.1M
-$62.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Upstream Bio has a last 12-month revenue of $2.1M and a last 12-month EBITDA of -$96.1M.
In the most recent fiscal year, Upstream Bio achieved revenue of $2.4M and an EBITDA of -$77.7M.
Upstream Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Upstream Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.4M | $2.4M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$40.1M | -$77.7M | XXX | XXX | XXX |
| EBITDA Margin | -1683% | -3277% | XXX | XXX | XXX |
| Net Profit | -$23.9M | -$20.5M | XXX | XXX | XXX |
| Net Margin | -1003% | -867% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Upstream Bio's stock price is $8.
Upstream Bio has current market cap of $407M, and EV of -$62.0M.
See Upstream Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$62.0M | $407M | XXX | XXX | XXX | XXX | $-4.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Upstream Bio has market cap of $407M and EV of -$62.0M.
Upstream Bio's trades at -29.3x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.
Analysts estimate Upstream Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Upstream Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$62.0M | XXX | XXX | XXX |
| EV/Revenue | -26.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.8x | XXX | XXX | XXX |
| P/E | -6.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpUpstream Bio's NTM/LTM revenue growth is -29%
Upstream Bio's revenue per employee for the last fiscal year averaged $46K, while opex per employee averaged $1.5M for the same period.
Over next 12 months, Upstream Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Upstream Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Upstream Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -3277% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 94% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -3306% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $46K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 724% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2657% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 3381% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Upstream Bio acquired XXX companies to date.
Last acquisition by Upstream Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Upstream Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Upstream Bio founded? | Upstream Bio was founded in 2021. |
| Where is Upstream Bio headquartered? | Upstream Bio is headquartered in United States of America. |
| How many employees does Upstream Bio have? | As of today, Upstream Bio has 52 employees. |
| Who is the CEO of Upstream Bio? | Upstream Bio's CEO is Dr. Everett Rand Sutherland, M.D.. |
| Is Upstream Bio publicy listed? | Yes, Upstream Bio is a public company listed on NAS. |
| What is the stock symbol of Upstream Bio? | Upstream Bio trades under UPB ticker. |
| When did Upstream Bio go public? | Upstream Bio went public in 2024. |
| Who are competitors of Upstream Bio? | Similar companies to Upstream Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Upstream Bio? | Upstream Bio's current market cap is $407M |
| What is the current revenue of Upstream Bio? | Upstream Bio's last 12-month revenue is $2.1M. |
| What is the current EBITDA of Upstream Bio? | Upstream Bio's last 12-month EBITDA is -$96.1M. |
| What is the current EV/Revenue multiple of Upstream Bio? | Current revenue multiple of Upstream Bio is -29.3x. |
| What is the current EV/EBITDA multiple of Upstream Bio? | Current EBITDA multiple of Upstream Bio is 0.6x. |
| What is the current revenue growth of Upstream Bio? | Upstream Bio revenue growth between 2023 and 2024 was 0%. |
| Is Upstream Bio profitable? | Yes, Upstream Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
